AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Envelaf 37.5mg Tablet XR

Prescription Icon
Prescription Required

Marketer

Alkem Laboratories Ltd

Salt Composition

Venlafaxine (37.5mg)

Overview Envelaf 37.5mg Tablet XR

Axilon 37.5mg Extended-Release Tablets treat depression and anxiety. It modifies brain chemistry, alleviating anxiety symptoms like agitation, hyperactivity, poor focus, tiredness, perspiration, rapid heartbeat, and racing thoughts. Take Axilon 37.5mg ER tablets with food, consistently at the same time daily for stable blood levels. If a dose is missed, take it immediately upon recall. Complete the prescribed course, even if feeling improved; abruptly stopping may worsen symptoms. Common side effects include queasiness, vomiting, sleeplessness, reduced appetite, nervousness, bowel irregularity, increased sweating, and sexual difficulties. Drowsiness and dizziness may occur; avoid driving or tasks requiring alertness until effects are known. These effects are generally transient. Report persistent or bothersome side effects to your physician. Before starting Axilon 37.5mg ER, disclose any kidney, heart, or liver issues, or history of seizures. Report any unusual mood shifts, worsening depression, or suicidal ideation to your doctor.

Uses of Envelaf 37.5mg Tablet XR

Mood disorders encompassing depressive and anxious symptoms

Major Benefits of Envelaf 37.5mg Tablet XR:

Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the 37.5mg Envelaf XR tablet whole; avoid crushing, chewing, or breaking it. Administer this medication with a meal.

Common Side effects of Envelaf 37.5mg Tablet XR:

  • Nausea
  • Vomiting
  • Dizziness
  • Insomnia (difficulty in sleeping)
  • Decreased appetite
  • Anxiety
  • Constipation
  • Increased sweating
  • Sexual dysfunction

How to use Envelaf 37.5mg Tablet XR:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the entire tablet; do not chew, crush, or divide it. Administer Envelaf 37.5mg Extended-Release Tablet with food.

How Envelaf 37.5mg Tablet XR works:

Envelaf 37.5mg Extended-Release tablets elevate brain levels of serotonin and noradrenaline, neurotransmitters crucial for emotional equilibrium.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Envelaf 37.5mg Tablet XR with alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Envelaf 37.5mg tablets may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescribing. Physician consultation is advised.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Envelaf 37.5mg tablets are likely unsafe for breastfeeding mothers. Available human data indicates potential drug transfer to breast milk, posing a risk to the infant. Infants should be observed for signs of drowsiness and monitored for appropriate weight increase.

DrivingDrivingUNSAFE

Driving ability may be impaired by Envelaf 37.5mg Tablet XR, a medication that can produce side effects including dizziness, confusion, and visual disturbances like blurred vision.

KidneyKidneyCAUTION

Extended-release Envelaf 37.5mg tablets require careful administration for individuals with impaired kidney function. Dosage modification of Envelaf 37.5mg XR tablets may be necessary. Physician consultation is advised.

LiverLiverCAUTION

Exercise caution when administering Envelaf 37.5mg extended-release tablets to individuals with hepatic impairment. Dosage modification may be necessary. Physician consultation is advised.

What if you forget to take Envelaf 37.5mg Tablet XR :

Should you forget to take a 37.5mg extended-release Envelaf tablet, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Envelaf 37.5mg Tablet XR

LabelValue
Type of Compound Methoxybenzene compound
Addictive None.
Medication Classification Nervous system medication.
Mechanism of Action Drugs that block the reabsorption of serotonin and norepinephrine.

FAQs on Envelaf 37.5mg Tablet XR

Indeed, Envelaf 37.5mg extended-release tablets may induce drowsiness. Prior to commencing Envelaf 37.5mg extended-release tablets, disclose any concurrent use of sleep aids to your physician.
Affirmative. Envelaf 37.5mg extended-release tablets are classified as a psychotropic medication. Psychotropic medications are defined as those impacting mental processes, mood, and behavior.
Envelaf 37.5mg Extended-Release Tablets are not classified as narcotics. Narcotics are opioid-derived substances, such as heroin and morphine, known for their sedative effects.
Identical medications, Envelaf 37.5mg Tablet XR and ER formulations, are both extended-release preparations. This slow release maintains consistent therapeutic drug levels. Extended-release tablets reduce the required dosing frequency.
Mirtazapine combined with Envelaf 37.5mg Tablet XR carries a significant risk of serotonin syndrome. This potentially fatal condition may manifest as agitation, hallucinations, nausea, vomiting, diarrhea, rapid heart rate, fluctuating blood pressure, fever, and coma. Therefore, concurrent use is not recommended.
Concurrent use of citalopram and Envelaf 37.5mg extended-release tablets elevates serotonin levels, posing a risk of serotonin syndrome. This potentially fatal condition manifests as agitation, hallucinations, gastrointestinal distress (nausea, vomiting, diarrhea), rapid heart rate, fluctuating blood pressure, elevated body temperature, and coma. Alternative medications should be considered.
Envelaf 37.5mg Tablet XR is actively removed from the brain by p-glycoprotein. Research indicates that Envelaf 37.5mg Tablet XR and its byproduct can suppress p-glycoprotein activity.
Extended-release Envelaf 37.5mg tablets are absorbed into the body via the intestinal tract following hepatic metabolism.
Extended-release Envelaf tablets (37.5mg) are prescribed for the management of major depressive disorder. Physician consultation is required prior to use.
Prolonged use of Envelaf 37.5mg Extended-Release tablets may elevate blood pressure in certain individuals. Regular blood pressure checks are advised for patients taking Envelaf 37.5mg Extended-Release tablets. Dosage adjustment or treatment cessation may be necessary in these cases.
Constipation is a reported side effect of Envelaf 37.5mg Extended-Release tablets in certain individuals. Increased fluid intake and a high-fiber diet are recommended. Laxative use may also be considered. Your physician can provide guidance on prevention and management. Seek medical attention if constipation persists or worsens.
Confirmed. Envelaf 37.5mg extended-release tablets have been associated with weight reduction in a subset of individuals. Clinical trials revealed a correlation between dosage and weight change in those receiving Envelaf 37.5mg extended-release tablets over an extended period. Discuss this side effect with your physician if it is concerning.
Envelaf 37.5mg extended-release tablets are not considered habit-forming.
Substituting a tablet for a capsule requires a physician's approval. Self-modification is inadvisable, as differing drug formulations affect medication release and consequently treatment efficacy. This alteration may result in suboptimal treatment, adverse reactions, or treatment failure.
Concurrent use of gabapentin and Envelaf 37.5mg extended-release tablets is permissible, but only under strict medical supervision. This combination may heighten drowsiness, lethargy, and impair concentration. Proceed with caution.
Desvenlafaxine, a pharmacologically active byproduct of the extended-release Envelaf 37.5mg Tablet, represents the medication's therapeutically active component.
Extended-release Envelaf 37.5mg tablets are not officially indicated for fibromyalgia. Preliminary research suggests potential benefits in fibromyalgia treatment using this formulation. Physician consultation is advised prior to commencing this medication.
Extended-release Envelaf 37.5mg tablets lack regulatory approval for neuropathic pain, yet independent studies suggest effectiveness in managing this condition. Consequently, its use for nerve pain is currently considered off-label.
Extended-release Envelaf 37.5mg tablets can alter brain neurotransmitter and chemical levels, resulting in reduced appetite. This appetite suppression is correlated with the administered dose.
Experience reduced libido or erectile dysfunction? Consult your physician to explore alternative treatment options. Do not discontinue Envelaf 37.5mg Tablet XR independently; this may worsen side effects.
Envelaf 37.5mg Tablet XR
23
MRP 28
17% off